J&J's Darzalex combination gains expanded label for multiple myeloma in Europe

By Yahoo! Finance | Oct 23, 2024 at 05:08 PM EST

The European label for J&J's Darzalex has been expanded to include newly diagnosed multiple myeloma patients eligible for stem cell transplant. Supported by Phase III trial data, the antibody is projected to generate significant revenue growth by 2030.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.